Nam H K Nguyen
Overview
Explore the profile of Nam H K Nguyen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
27
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nguyen N, Nguyen N, Rafiee R, Parcha P, Parcha P, Tagmount A, et al.
Blood Adv
. 2024 Dec;
9(5):1078-1091.
PMID: 39715471
Cytarabine, daunorubicin, and etoposide (ADE) have been the standard backbone of induction chemotherapy regimen for patients with pediatric acute myeloid leukemia (pAML) for >5 decades. However, chemoresistance is still a...
2.
H Elsayed A, Cao X, Marrero R, Nguyen N, Wu H, Ni Y, et al.
NPJ Precis Oncol
. 2024 Aug;
8(1):168.
PMID: 39090192
In this study, we leveraged machine-learning tools by evaluating expression of genes of pharmacological relevance to standard-AML chemotherapy (ara-C/daunorubicin/etoposide) in a discovery-cohort of pediatric AML patients (N = 163; NCT00136084...
3.
Oni-Orisan A, Tuteja S, Hoffecker G, Smith D, Castrichini M, Crews K, et al.
Clin Pharmacol Ther
. 2023 Jun;
114(2):275-287.
PMID: 37303270
Pharmacogenetics can improve clinical outcomes by reducing adverse drug effects and enhancing therapeutic efficacy for commonly used drugs that treat a wide range of cardiovascular diseases. One of the major...
4.
Fradley M, Nguyen N, Madnick D, Chen Y, DeMichele A, Makhlin I, et al.
J Am Heart Assoc
. 2023 Jun;
12(12):e029361.
PMID: 37301767
Background Cyclin-dependent kinase (CDK) 4 and 6 inhibitors have significantly improved survival in patients with hormone receptor-positive metastatic breast cancer. There are few data regarding the epidemiology of cardiovascular adverse...
5.
Nguyen N, Rafiee R, Tagmount A, Sobh A, Loguinov A, de Jesus Sosa A, et al.
Blood Adv
. 2022 Sep;
7(9):1769-1783.
PMID: 36111891
Etoposide is used to treat a wide range of malignant cancers, including acute myeloid leukemia (AML) in children. Despite the use of intensive chemotherapeutic regimens containing etoposide, a significant proportion...
6.
Armstrong N, Srinivasasainagendra V, Chekka L, Nguyen N, Nahid N, Jones A, et al.
Genes (Basel)
. 2022 Jul;
13(7).
PMID: 35886043
Hypertension is a leading risk factor for cardiovascular disease mortality. African Americans (AAs) have the highest prevalence of hypertension in the United States, and to alleviate the burden of hypertension...
7.
Gbadamosi M, Shastri V, H Elsayed A, Ries R, Olabige O, Nguyen N, et al.
Leukemia
. 2022 Jun;
36(8):2022-2031.
PMID: 35688939
Gemtuzumab ozogamicin (GO) is an anti-CD33 monoclonal antibody linked to calicheamicin, a DNA damaging agent, and is a well-established therapeutic for treating acute myeloid leukemia (AML). In this study, we...
8.
Nguyen N, Wu H, Tan H, Peng J, Rubnitz J, Cao X, et al.
Cancers (Basel)
. 2021 Jul;
13(13).
PMID: 34202615
Acute Myeloid Leukemia (AML) is a heterogeneous disease with several recurrent cytogenetic abnormalities. Despite genomics and transcriptomics profiling efforts to understand AML's heterogeneity, studies focused on the proteomic profiles associated...